Physician profile
Daniel C Garibaldi
NPI 1194779678
$4,227.61
in general payments reported to CMS, 2019-2025
24 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $261 · 2021: $281 · 2022: $569 · 2023: $611 · 2024: $1,092 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,032.75 | 2019-2023 | Tepezza |
| Abbvie INC. | $543.71 | 2024-2025 | |
| Amgen INC. | $514.90 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $407.91 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $390.49 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $344.23 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Novartis Pharmaceuticals Corporation | $136.01 | 2020-2022 | |
| Genentech USA, INC. | $119.45 | 2019-2025 | Vabysmo |
| Tearlab Corp | $112.66 | 2024 | Scoutpro Osmolarity System |
| Eyevance Pharmaceuticals LLC | $110.52 | 2019-2022 | |
| Oyster Point Pharma, INC. | $90.28 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $74.12 | 2019-2021 | |
| Merz North America, INC. | $61.94 | 2024-2025 | |
| Alcon Vision LLC | $46.33 | 2025 | Simbrinza |
| Kala Pharmaceuticals, INC. | $32.98 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $30.70 | 2023-2025 | Syfovre |
| Glaukos Corporation | $28.05 | 2025 | Photrexa Viscous and Photrexa |
| Mallinckrodt Hospital Products INC. | $24.98 | 2024 | Acthar |
| Galderma Laboratories, L.P. | $23.79 | 2020 | |
| Bausch & Lomb Americas INC. | $23.45 | 2023 | Vyzulta |
| Beaver-Visitec International, INC. | $20.97 | 2023 | |
| Thea Pharma INC. | $20.06 | 2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $19.33 | 2023 | Cequa |
| Dompe US, INC. | $18.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Garibaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.